QuidelOrtho has significantly lowered its financial guidance for fiscal year 2026, reducing adjusted EPS expectations by more than 50% and sales guidance by approximately 6-8%. This substantial downward revision indicates a material deterioration in the company's projected financial performance, likely leading to a negative market reaction.
QuidelOrtho has issued a stark warning to investors by drastically cutting its fiscal year 2026 adjusted EPS guidance from $1.80-$2.00 to $0.65-$0.90, and sales guidance from $2.700B-$2.750B to $2.520B-$2.600B. This represents a significant reduction, with the new EPS range falling well below analyst estimates of $1.84. The immediate impact will be a sharp negative reaction in QDEL's stock price as investors re-evaluate the company's future prospects. This guidance cut suggests underlying operational challenges, competitive pressures, or a weaker-than-expected market for its products, which could have long-term implications for its growth trajectory and market share. Traders should anticipate significant downward pressure on QDEL shares and potential re-rating by analysts.